Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients
Sander F. Garrelfs(Emma Kinderziekenhuis), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Dewi van Harskamp(Emma Kinderziekenhuis), Ronald J. A. Wanders(Amsterdam University Medical Centers), Jaap W. Groothoff(University of Amsterdam), Henk Schierbeek(Emma Kinderziekenhuis), Chris H.P. van den Akker(Amsterdam University Medical Centers), Hessel Peters‐Sengers(Amsterdam Neuroscience), Frits A. Wijburg(Emma Kinderziekenhuis), Johannes B. van Goudoever(Emma Kinderziekenhuis)
Cited by 21
Related Papers
Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies
|Nature Medicine|2014|843
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
|Proceedings of the National Academy of Sciences|2008|725
Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia
|Orphanet Journal of Rare Diseases|2014|713
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update
|Molecular Genetics and Metabolism|2012|478